Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Intraperitoneal Aerosolization of Albumin-stabilized Paclitaxel Nanoparticles for Stomach, Pancreas, Breast and Ovarian Cancer

Trial Profile

Intraperitoneal Aerosolization of Albumin-stabilized Paclitaxel Nanoparticles for Stomach, Pancreas, Breast and Ovarian Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 20 Aug 2018

At a glance

  • Drugs Paclitaxel (Primary)
  • Indications Advanced breast cancer; Carcinoma; Gastrointestinal cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PIPAC-nabpac
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 24 May 2018 Phase has been changed from I/II to I. Parallel assignment has been changed to single group assignment. treatment arm has been changed. Efficacy endpoint has been removed. Planned patient number has been changed from 70 to 20. Gender has been changed from female to male and female both.
    • 24 May 2018 Planned number of patients changed from 70 to 20.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top